Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; “Renalys”) announced today that it has completed data collection for the primary endpoint in the Phase III clinical trial of sparsentan (development code: RE-021) for IgA nephropathy in Japan. The primary endpoint evaluated was the urine protein creatinine ratio (24-hour urine collection) at 36 weeks and data have now […]